SCHEMBL11946141

SCHEMBL11946141

CC[C@H]1C[C@@H]1COc1c(N2CCN(C)CC2)cnn(-c2cc(F)cc(F)c2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SLC2A1 P11166 1/20 0.34
▸ SLC2A3 P11169 1/20 0.34
▸ ALDH1A1 P00352 7/20 0.33
▸ CYP1A2 P05177 6/20 0.33
▸ HSD17B10 Q99714 6/20 0.33
▸ CASP1 P29466 6/20 0.33
▸ CASP7 P55210 6/20 0.33
▸ USP2 O75604 6/20 0.33
▸ HIF1A Q16665 6/20 0.33
▸ CYP2C9 P11712 4/20 0.33
▸ GLA P06280 1/20 0.33
▸ CYP3A4 P08684 6/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946144 0.92 POLB (0.39) POLBSMN1; SMN2LMNAKMT2ASLC2A1
SCHEMBL11946143 0.91 POLB (0.39) POLBSMN1; SMN2LMNAKMT2ASLC2A1
SCHEMBL11946142 0.89 POLB (0.37) POLBSMN1; SMN2LMNAKMT2ASLC2A1
SCHEMBL11946130 0.82 MAPT (0.39) POLBSLC2A1SLC2A3ALDH1A1HSD17B10
SCHEMBL11946220 0.82 MAPT (0.39) POLBSLC2A1SLC2A3ALDH1A1HSD17B10
SCHEMBL11946145 0.81 CYP3A4 (0.34) POLBLMNAKMT2ASLC2A1SLC2A3
SCHEMBL17058088 0.80 ALDH1A1 (0.35) LMNAKMT2ASLC2A1SLC2A3ALDH1A1
SCHEMBL11946125 0.80 POLB (0.40) POLBSMN1; SMN2LMNAKMT2ASLC2A1
SCHEMBL11946148 0.79 POLB (0.36) POLBSLC2A1SLC2A3ALDH1A1CYP3A4
SCHEMBL11946122 0.77 POLB (0.39) POLBSMN1; SMN2LMNAKMT2ASLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885SMN1; SMN2 3911/4885LMNA 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback